{
  "id": "61f7d2a5882a024a10000032",
  "type": "yesno",
  "question": "Is Belimumab used for lupus nephritis?",
  "ideal_answer": "Yes, Belimumab can be used for lupus nephritis.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/34560137",
    "http://www.ncbi.nlm.nih.gov/pubmed/30184477",
    "http://www.ncbi.nlm.nih.gov/pubmed/22584472",
    "http://www.ncbi.nlm.nih.gov/pubmed/33186226",
    "http://www.ncbi.nlm.nih.gov/pubmed/32002799",
    "http://www.ncbi.nlm.nih.gov/pubmed/34244988",
    "http://www.ncbi.nlm.nih.gov/pubmed/29514612",
    "http://www.ncbi.nlm.nih.gov/pubmed/25005336",
    "http://www.ncbi.nlm.nih.gov/pubmed/25969652",
    "http://www.ncbi.nlm.nih.gov/pubmed/34521616",
    "http://www.ncbi.nlm.nih.gov/pubmed/34469086",
    "http://www.ncbi.nlm.nih.gov/pubmed/34600347"
  ],
  "snippets": [
    {
      "text": "In particular, depletion (Obinutuzumab, anti-CD20 monoclonal antibody) or neutralization (Belimumab, anti-\"B-cell activating factor\" monoclonal antibody) of B lymphocytes, and the use of a calcineurin inhibitor with a low profile of renal and systemic toxicity (Voclosporin) demonstrated an improvement in renal response in addition to standard therapy.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34469086",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "In this viewpoint, we discuss the pros and cons of voclosporin and belimumab as add-on agents to standard therapy, the first drugs to be licenced for lupus nephritis after recent successful randomised phase III clinical trials. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34521616",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Durable renal response and safety with add-on belimumab in patients with lupus nephritis in real-life setting (BeRLiSS-LN).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34600347",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "A secondary analysis of the Belimumab International Study in Lupus Nephritis trial examined effects of belimumab on kidney outcomes and preservation of kidney function in patients with lupus nephritis.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34560137",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Thus, our data suggest that the addition of belimumab to standard therapy could attenuate the risk of lupus nephritis flare and eGFR decline in a broad spectrum of patients with lupus nephritis.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34560137",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Belimumab and low-doses of mycophenolate mofetil as induction therapy of class IV lupus nephritis: case series and literature review.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29514612",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "JECTIVE: To describe a patient whose active SLE (including lupus nephritis) was managed with the use of belimumab throughout pregnancy.ME",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25005336",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Recently introduced into the market, belimumab (Benlysta) is a monoclonal antibody that has potential clinically efficacious applications for the treatment of lupus nephritis.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25969652",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "With vast implications through a novel mechanism, belimumab offers a new standard of treatment for physicians in the complications associated with SLE, specifically lupus nephritis.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25969652",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "CENT FINDINGS: Recently, the Belimumab in Subjects with Systemic Lupus Erythematosus - Lupus Nephritis trial tested belimumab, an inhibitor of B-cell activating factor, as an add-on therapy to steroids and either mycophenolate mofetil (MMF) or cyclophosphamide when given IV monthly over a period of 104 weeks at an effect size of 11% for a Primary Efficacy Renal Response. T",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33186226",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Recently introduced into the market, belimumab (Benlysta) is a monoclonal antibody that has potential clinically efficacious applications for the treatment of lupus nephritis. L",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25969652",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "st implications through a novel mechanism, belimumab offers a new standard of treatment for physicians in the complications associated with SLE, specifically lupus nephritis. By targ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25969652",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Efficacy of novel monoclonal antibody belimumab in the treatment of lupus nephritis",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25969652",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "ic agents, rituximab may be used for refractory lupus nephritis patients in combination with another DMARD, and belimumab was recently approved by the US Food and Drug Administration for cSLE treatment in children aged > 5 years. New therapies targeting CD20, suc",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34244988",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "s end, there is limited post-hoc randomized evidence to suggest beneficial effect of belimumab, administered on top of standard-of-care, during maintenance therapy in lupus nephritis. Type I ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30184477",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "e of recently approved belimumab in lupus nephritis eagerly awaits further documentation. Aggre",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/22584472",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Recently introduced into the market, belimumab (Benlysta) is a monoclonal antibody that has potential clinically efficacious applications for the treatment of lupus nephritis",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25969652",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Belimumab may decrease flare rate and allow glucocorticoid withdrawal in lupus nephritis (including dialysis and transplanted patient).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32002799",
      "beginSection": "title",
      "endSection": "title"
    }
  ],
  "concepts": [],
  "exact_answer": "Yes"
}